|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. 
FIGURE 2-17 Conditional 5-year relative survival rates, breast cancer, by stage (modified American Joint Committee on Cancer [AJCC] staging). NOTE: For Figures 2-17 to 2-19, bars around the point estimates indicate 95 percent confidence intervals. SOURCE: Estimates based on NCI analyses of Surveillance, Epidemiology, and End Results (SEER) cancer registry data for cases diagnosed from 1993 to 2000 using SEER*Stat software and SEER 12 registries. Software: Surveillance Research Program, NCI SEER*Stat software (www.seer.cancer.gov/seerstat), version 6.0.0-beta. Data: SEER Program SEER*Stat database: Incidence—SEER 11 Regs + AK, Public Use Nov 2003 Sub (1973-2001 varying), NCI, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. are diagnosed at older ages and those with late-stage disease (e.g., pancreatic and lung cancer). The availability of screening tests for certain cancers has changed the composition of the survivorship population, increasing greatly the number of survivors living long term with preclinical and treatable early-stage disease. Differential use of these tests has contributed to an underrepresentation of certain groups in the survivorship population, for example, those with poor access to health care. Because there is unequal access to health care in the United States, significant disparities arise in cancer survivorship. This section will describe the nature of some of these
|
|
|||||||||||||||
